Company: TELO
Filing Date: 2025-02-14
Form Type: S-3
Source: 0001493152-25-006943
Chunk: 25

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-02-14
Form: S-3
Chunk 25
---
='center'>Telomir Pharmaceuticals, Inc.

Attention: Corporate Secretary

100 SE 2nd St, Suite 2000, #1009

Miami, Florida 33131

Telephone number: (786) 396-6723</div>

You should not assume that the information in this prospectus or any prospectus supplement, as well as the information we file or previously filed with the SEC that we incorporate by reference in this prospectus or any prospectus supplement, is accurate as of any date other than the respective date of such documents. Our business, financial condition, results of operations and prospects may have changed since that date.

| 16 |

PROSPECTUS

<div align='center'>$150,000,000

TELOMIR PHARMACEUTICALS, INC.

Common Stock

Preferred Stock

Warrants

Units</div>

The information in this prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.

<div align='center'>SUBJECT TO COMPLETION, DATEDFEBRUARY 14 , 2025</div>

PROSPECTUS

<div align='center'>Telomir Pharmaceuticals, Inc.

Up to $100,000,000

Common Stock</div>

We have entered into an At The Market Offering Agreement, or the sales agreement, with Rodman & Renshaw LLC, or Rodman & Renshaw, dated February 14, 2025, relating to the sale of shares of our common stock, no par value, having an aggregate offering price of up to $100,000,000 from time to time through Rodman & Renshaw, acting as agent or principal.

Sales of our common stock, if any, under this prospectus will be made by any method permitted that is deemed an “at the market” offering as defined in Rule 415 under the Securities Act of 1933, as amended, or the Securities Act, including sales made directly on or through the Nasdaq Capital Market or any other existing trading market in the United States for our common stock, sales made to or through a market maker other than on an exchange or otherwise, directly to Rodman & Renshaw as principal, in negotiated transactions at market prices prevailing at the